Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein
FY 2022-23
Summary
Prion diseases, such as Creutzfeldt-Jakob Disease (CJD) and Bovine Spongiform Encephalopathy (BSE), also known as Mad Cow Disease, are fatal neurodegenerative diseases that afflict humans and animals. This research aims to discover a treatment for these diseases. We know that we could extend prion disease survival if we were able to reduce the levels of a particular protein, the cellular prion protein (PrPC). We also know that it would be safe to do so because individuals whose cells produce half the levels of PrPC can reach old age in good health and animals who produce no PrPC are similarly unaffected.
We recently discovered that PrPC binds to NKAs, specific cellular transport proteins that use energy to electrify cellular membranes by pumping charged potassium and sodium metals in and out of cells. We hypothesized that targeting NKAs with their natural inhibitors, cardiac glycosides (CGs), may cause cells to internalize and degrade NKAs, and that PrPC residing next to NKAs may get co-degraded. In preparation of this proposal, we have validated this idea in several relevant human cell models. We also have developed a novel CG that has favourable characteristics for brain applications.
The current proposal is informed by these data and will address independent, yet synergistic, aims that answer the question: Can treatment with CGs reduce the levels of PrPC and extend prion disease survival?
The project builds on substantial recently published data by our group that tie NKAs to prion diseases. In collaboration with an international team, we will provide proof-of-principle pre-clinical data for the treatment of prion diseases using a novel treatment modality. Moreover, the ability to suppress PrPC levels may translate into a treatment of Alzheimer's disease (AD), because PrPC is widely believed to be a critical player in a cascade of events that leads to the demise of brain cells in AD.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475657
Name
Eid Shehab
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Prion Diseases; Proteomics Mass Spectrometry; Small Molecule Drug Discovery
Abstract
Prion diseases, such as Creutzfeldt-Jakob Disease (CJD) and Bovine Spongiform Encephalopathy (BSE), also known as Mad Cow Disease, are fatal neurodegenerative diseases that afflict humans and animals. This research aims to discover a treatment for these diseases. We know that we could extend prion disease survival if we were able to reduce the levels of a particular protein, the cellular prion protein (PrPC). We also know that it would be safe to do so because individuals whose cells produce half the levels of PrPC can reach old age in good health and animals who produce no PrPC are similarly unaffected.
We recently discovered that PrPC binds to NKAs, specific cellular transport proteins that use energy to electrify cellular membranes by pumping charged potassium and sodium metals in and out of cells. We hypothesized that targeting NKAs with their natural inhibitors, cardiac glycosides (CGs), may cause cells to internalize and degrade NKAs, and that PrPC residing next to NKAs may get co-degraded. In preparation of this proposal, we have validated this idea in several relevant human cell models. We also have developed a novel CG that has favourable characteristics for brain applications.
The current proposal is informed by these data and will address independent, yet synergistic, aims that answer the question: Can treatment with CGs reduce the levels of PrPC and extend prion disease survival?
The project builds on substantial recently published data by our group that tie NKAs to prion diseases. In collaboration with an international team, we will provide proof-of-principle pre-clinical data for the treatment of prion diseases using a novel treatment modality. Moreover, the ability to suppress PrPC levels may translate into a treatment of Alzheimer's disease (AD), because PrPC is widely believed to be a critical player in a cascade of events that leads to the demise of brain cells in AD.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Eid, Shehab
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~